Healthcare - Biotechnology - NASDAQ - US
$ 0.6701
-6.12 %
$ 25.9 M
Market Cap
-0.24
P/E
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc.[ Read More ]
The intrinsic value of one ATHA stock under the base case scenario is HIDDEN Compared to the current market price of 0.67 USD, Athira Pharma, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart ATHA
FINANCIALS
0
REVENUE
-125 M
OPERATING INCOME
-118 M
NET INCOME
-101 M
OPERATING CASH FLOW
95.1 M
INVESTING CASH FLOW
493 K
FINANCING CASH FLOW
0
REVENUE
-29.6 M
OPERATING INCOME
-28.7 M
NET INCOME
-23 M
OPERATING CASH FLOW
18 M
INVESTING CASH FLOW
12 K
FINANCING CASH FLOW
Balance Sheet Decomposition
Athira Pharma, Inc.
| Current Assets | 155 M |
| Cash & Short-Term Investments | 147 M |
| Receivables | 1.63 M |
| Other Current Assets | 5.68 M |
| Non-Current Assets | 5.52 M |
| Long-Term Investments | 0 |
| PP&E | 4.44 M |
| Other Non-Current Assets | 1.08 M |
| Current Liabilities | 28.8 M |
| Accounts Payable | 129 K |
| Short-Term Debt | 736 K |
| Other Current Liabilities | 28 M |
| Non-Current Liabilities | 1.22 M |
| Long-Term Debt | 1.22 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Athira Pharma, Inc.
| Revenue | 0 |
| Cost Of Revenue | 969 K |
| Gross Profit | -969 K |
| Operating Expenses | 125 M |
| Operating Income | -125 M |
| Other Expenses | -7.79 M |
| Net Income | -118 M |
RATIOS
0.00%
GROSS MARGIN
0.00%
OPERATING MARGIN
0.00%
NET MARGIN
-90.39%
ROE
-73.43%
ROA
-96.10%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Athira Pharma, Inc.
| Net Income | -118 M |
| Depreciation & Amortization | 969 K |
| Capital Expenditures | -304 K |
| Stock-Based Compensation | 10.6 M |
| Change in Working Capital | 6.53 M |
| Others | -2.04 M |
| Free Cash Flow | -101 M |
Wall Street Analysts Price Targets
Athira Pharma, Inc.
ATHA has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Athira Pharma, Inc.
Sold
0-3 MONTHS
7.86 K USD 5
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
38.6 K USD 5
Bought
0 USD 0
0-3 MONTHS
100 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
1.46 M USD 1
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
2 months ago
Sep 05, 2024
|
Sell 720 USD
|
Gengos Andrew
CFO and Chief Business Officer |
- 1272
|
0.566 USD |
|
2 months ago
Sep 05, 2024
|
Sell 1.43 K USD
|
Lenington Rachel
COO and CDO |
- 2525
|
0.566 USD |
|
2 months ago
Sep 05, 2024
|
Sell 1.43 K USD
|
CHURCH KEVIN
CHIEF SCIENTIFIC OFFICER |
- 2525
|
0.566 USD |
|
2 months ago
Sep 05, 2024
|
Sell 1.43 K USD
|
Worthington Mark
GENERAL COUNSEL |
- 2525
|
0.566 USD |
|
2 months ago
Sep 05, 2024
|
Sell 2.85 K USD
|
Litton Mark James
President and CEO |
- 5032
|
0.566 USD |
|
4 months ago
Jun 24, 2024
|
Bought 66.2 K USD
|
Romano Kelly A
Director |
+ 27400
|
2.4153 USD |
|
4 months ago
Jun 21, 2024
|
Bought 33.9 K USD
|
Romano Kelly A
Director |
+ 15000
|
2.2581 USD |
|
10 months ago
Jan 05, 2024
|
Sell 3.52 K USD
|
Gengos Andrew
CFO AND CHIEF BUSINESS OFFICER |
- 1208
|
2.91 USD |
|
10 months ago
Jan 05, 2024
|
Sell 7.02 K USD
|
CHURCH KEVIN
CHIEF SCIENTIFIC OFFICER |
- 2412
|
2.91 USD |
|
1 year ago
Jan 05, 2023
|
Sell 3.52 K USD
|
Gengos Andrew
See Below |
- 1208
|
2.91 USD |
|
10 months ago
Jan 05, 2024
|
Sell 14 K USD
|
Litton Mark James
Chief Executive Officer |
- 4820
|
2.91 USD |
|
10 months ago
Jan 05, 2024
|
Sell 7.02 K USD
|
Worthington Mark
General Counsel |
- 2412
|
2.91 USD |
|
1 year ago
Jan 05, 2023
|
Sell 7.02 K USD
|
CHURCH KEVIN
Chief Scientific Officer |
- 2412
|
2.91 USD |
|
10 months ago
Jan 05, 2024
|
Sell 7.02 K USD
|
Lenington Rachel
Chief Operating Officer |
- 2412
|
2.91 USD |
|
10 months ago
Dec 29, 2023
|
Bought 390 K USD
|
PERCEPTIVE ADVISORS LLC
director, 10 percent owner: |
+ 163954
|
2.38 USD |
|
10 months ago
Dec 28, 2023
|
Bought 999 K USD
|
PERCEPTIVE ADVISORS LLC
director, 10 percent owner: |
+ 409598
|
2.44 USD |
|
10 months ago
Dec 27, 2023
|
Bought 73.3 K USD
|
PERCEPTIVE ADVISORS LLC
director, 10 percent owner: |
+ 32134
|
2.28 USD |
|
1 year ago
Jun 07, 2023
|
Bought 40.3 K USD
|
Gengos Andrew
See Below |
+ 11719
|
3.4395 USD |
|
1 year ago
Jun 07, 2023
|
Bought 9.72 K USD
|
Gengos Andrew
See Below |
+ 2859
|
3.4 USD |
|
1 year ago
Jun 07, 2023
|
Bought 1.42 K USD
|
Gengos Andrew
See Below |
+ 422
|
3.3576 USD |
|
1 year ago
Jun 05, 2023
|
Bought 30.2 K USD
|
Gengos Andrew
See Below |
+ 10000
|
3.0154 USD |
|
1 year ago
Jun 05, 2023
|
Bought 30 K USD
|
Gengos Andrew
See Below |
+ 10000
|
2.9999 USD |
|
1 year ago
Jun 05, 2023
|
Bought 30 K USD
|
Gengos Andrew
See Below |
+ 10000
|
2.9997 USD |
|
1 year ago
Jun 05, 2023
|
Bought 45 K USD
|
Gengos Andrew
See Below |
+ 15000
|
3 USD |
|
1 year ago
Jun 02, 2023
|
Bought 10.1 K USD
|
Gengos Andrew
See Below |
+ 3418
|
2.945 USD |
|
1 year ago
Jun 02, 2023
|
Bought 18.8 K USD
|
Gengos Andrew
See Below |
+ 6582
|
2.8598 USD |
|
1 year ago
Jun 02, 2023
|
Bought 27.5 K USD
|
Gengos Andrew
See Below |
+ 10012
|
2.75 USD |
|
1 year ago
Mar 30, 2023
|
Bought 37 K USD
|
PICKERING GRANT
Director |
+ 15000
|
2.47 USD |
|
1 year ago
Mar 29, 2023
|
Bought 23.3 K USD
|
PICKERING GRANT
Director |
+ 10000
|
2.33 USD |
|
1 year ago
Mar 29, 2023
|
Bought 12 K USD
|
JOHNSON JAMES A
Director |
+ 5000
|
2.4 USD |
|
1 year ago
Dec 28, 2022
|
Bought 142 K USD
|
MILESON GLENNA
Chief Financial Officer |
+ 50000
|
2.845 USD |
|
1 year ago
Dec 02, 2022
|
Bought 98.7 K USD
|
Romano Kelly A
Director |
+ 30000
|
3.29 USD |
|
2 years ago
Nov 15, 2022
|
Bought 16.4 K USD
|
MOEBIUS HANS
Chief Medical Officer |
+ 5000
|
3.2884 USD |
|
2 years ago
Jun 30, 2022
|
Bought 3.29 M USD
|
PERCEPTIVE ADVISORS LLC
director, 10 percent owner: |
+ 1101362
|
2.99 USD |
|
2 years ago
Jun 29, 2022
|
Bought 807 K USD
|
EDELMAN JOSEPH
director: |
+ 270000
|
2.99 USD |
|
2 years ago
Jun 29, 2022
|
Bought 807 K USD
|
PERCEPTIVE ADVISORS LLC
director, 10 percent owner: |
+ 270000
|
2.99 USD |
|
2 years ago
Jun 28, 2022
|
Bought 28.8 K USD
|
MOEBIUS HANS
Chief Medical Officer |
+ 10000
|
2.88 USD |
|
2 years ago
Jun 22, 2022
|
Sell 7.03 K USD
|
Worthington Mark
General Counsel |
- 2614
|
2.69 USD |
|
2 years ago
Jun 22, 2022
|
Sell 7.03 K USD
|
MILESON GLENNA
Chief Financial Officer |
- 2614
|
2.69 USD |
|
2 years ago
Jun 22, 2022
|
Sell 21.4 K USD
|
Litton Mark James
Chief Executive Officer |
- 7960
|
2.69 USD |
|
2 years ago
Jun 22, 2022
|
Sell 11.3 K USD
|
Lenington Rachel
Chief Operating Officer |
- 4193
|
2.69 USD |
|
2 years ago
Jun 22, 2022
|
Sell 7.03 K USD
|
CHURCH KEVIN
Executive VP, Research |
- 2614
|
2.69 USD |
|
2 years ago
Mar 31, 2022
|
Bought 105 K USD
|
Romano Kelly A
director: |
+ 8000
|
13.11 USD |
|
3 years ago
Jan 25, 2021
|
Bought 7 M USD
|
PERCEPTIVE ADVISORS LLC
director, 10 percent owner: |
+ 311111
|
22.5 USD |
|
4 years ago
Sep 22, 2020
|
Bought 18 M USD
|
PERCEPTIVE ADVISORS LLC
10 percent owner |
+ 1058824
|
17 USD |
|
4 years ago
Sep 22, 2020
|
Bought 18 M USD
|
EDELMAN JOSEPH
director, 10 percent owner: |
+ 1058824
|
17 USD |
|
4 years ago
Sep 18, 2020
|
Bought 12.8 M USD
|
RTW INVESTMENTS, LP
10 percent owner |
+ 750000
|
17 USD |
7. News
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025 Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025
globenewswire.com
- 1 week ago
ATHA Energy appoints seasoned experts to leadership team
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has announced the appointment of Erinn Broshko as a non-executive director and Rhéal Assié as chief financial officer, starting November 6. The company said Broshko, a seasoned executive and lawyer, brings more than 25 years of experience in law, business, and leadership, including roles as CEO and executive chairman in biotech and energy services.
proactiveinvestors.com
- 2 weeks ago
ATHA Energy and Terra Uranium enter into strategic option agreements on key uranium projects
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) announced that it has entered into option agreement with Terra Uranium Ltd (ASX:T92) which allow the two companies to earn significant interest in each other's uranium exploration projects. ATHA has granted Terra Uranium an option to acquire up to 70% interest in its Spire and Horizon properties, together the Spire Horizon projects.
proactiveinvestors.com
- 1 month ago
ATHA Energy Announces Option Agreements With Terra Uranium for Spire, Horizon, and Pasfield Projects
VANCOUVER, British Columbia, Oct. 11, 2024 (GLOBE NEWSWIRE) -- ATHA Energy Corp. (CSE: SASK) (FRA: X5U) (OTCQB: SASKF) (“ATHA”) is pleased to announce, in furtherance to its news release from August 20th, 2024 , the Company and Terra Uranium Ltd. (ASX: T92) (“T92”) have executed a definitive option agreement for T92 to earn an option to acquire a 70% interest in ATHA's Spire and Horizon properties (together, the “Spire Horizon Projects”) and a definitive option agreement for ATHA to earn an option to acquire up to a 60% interest in T92's Pasfield Lake property (the “Pasfield Project”).
globenewswire.com
- 1 month ago
ATHA Energy CEO highlights 2024 growth priorities at TD Securities Nuclear Roundtable
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) CEO Troy Boisjoli highlighted the company's aggressive growth strategy and plans for the year ahead in a discussion at the TD Securities Annual Nuclear Fuel Cycle and Next Generation Nuclear Roundtable. ATHA, listed in April 2023, has rapidly expanded its uranium exploration portfolio.
proactiveinvestors.com
- 1 month ago
ATHA Energy secures entire Lac 50 structural corridor at Angilak uranium project
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has expanded its Angilak Project in Nunavut by acquiring the entire Lac 50 structural corridor, along with an additional prospective parallel corridor. Both corridors are linked to the Snowbird Tectonic Zone, a significant crustal structure that extends from the Athabasca Basin to the Angikuni Basin.
proactiveinvestors.com
- 1 month ago
Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring
Seattle-based biotech company Athira Pharma is laying off 49 people, or about 70% of its workforce, as part of cost-cutting measures and a restructuring.
geekwire.com
- 1 month ago
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of ALS patients expected in 2025
globenewswire.com
- 1 month ago
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal
Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.
zacks.com
- 2 months ago
Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks
On Wednesday, Athira Pharma, Inc. ATHA stock is trading lower after the company released topline results from its Phase 2/3 LIFT-AD clinical trial of fosgonimeton for mild-to-moderate Alzheimer's disease (AD).
benzinga.com
- 2 months ago
Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial
Athira Pharma said on Tuesday its investigative drug failed to meet the main goal in a mid-to-late stage trial in patients with mild-to-moderate Alzheimer's disease.
reuters.com
- 2 months ago
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease
LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23)
globenewswire.com
- 2 months ago
8. Profile Summary
Athira Pharma, Inc. ATHA
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 25.9 M
Dividend Yield
0.00%
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Contact
18706 North Creek Parkway, Bothell, WA, 98011
https://www.athira.com
IPO Date
Sept. 18, 2020
Employees
65
Officers
Mr. Mark F. Worthington J.D.
General Counsel, Chief Compliance Officer & Corporate Secretary
Dr. Javier San Martin M.D.
Chief Medical Officer
Ms. Julie Rathbun
Head of Investor Relations
Mr. Robert Renninger
Vice President of Finance, Principal Financial Officer & Principal Accounting Officer
Dr. Kevin Church Ph.D.
Chief Scientific Officer
Dr. Mark J. Litton M.B.A., Ph.D.
President, Chief Executive Officer & Director